In this study, we demonstrated that endothelial-specific Sp1/Sp3 deletion resulted in endothelial dysfunction and hypertension, and that captopril, an ACE inhibitor and traditional antihypertensive drug, exerted part of its pharmacological effect by modulating Sp1/Sp3 levels in endothelial cells. The gene discussed is SP3; the disease is endothelial dysfunction.